GSK plc (GSK)
| Market Cap | 93.43B |
| Revenue (ttm) | 39.41B |
| Net Income (ttm) | 5.75B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.75 |
| PE Ratio | 16.57 |
| Forward PE | 10.32 |
| Dividend | $1.50 (3.29%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 186,429 |
| Open | 45.82 |
| Previous Close | 45.66 |
| Day's Range | 45.78 - 45.81 |
| 52-Week Range | 33.33 - 45.84 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 46.00 (+0.43%) |
| Earnings Date | May 1, 2024 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GSK stock is "Strong Buy." The 12-month stock price forecast is $46.0, which is an increase of 0.43% from the latest price.
News
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for seri...
5 best blue chip stocks to invest in for sustainable gains in May – excluding Apple Inc. (AAPL)
Yesterday, the biggest company in the world in terms of market cap reported its latest earnings. But Apple Inc. is far from the only blue chip stock around.
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Inge...
GSK raises full-year profit forecast
GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo...
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting indu...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1...
GSK says efficacy of its shingles vaccine remains high after years
British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccina...
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has regained full ownership from GSK of HTL0027477 (formerly GSK4381...
GSK to cap out-of-pocket inhaler costs in US
British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United St...
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients
Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the latest f...
AHF Urges Trinidad and Tobago to Sidestep Greedy GSK
LOS ANGELES--(BUSINESS WIRE)-- #AIDS--AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK an...
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
PHILADELPHIA--(BUSINESS WIRE)--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise.
GSK's blood cancer drug meets main goal in late-stage trial; analysts tout comeback
GSK said on Thursday a study showed its experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug a...
WHO says resistance to GSK's HIV drug is growing
The World Health Organization said on Tuesday that data shows resistance to the drug is growing in patients receiving GSK's HIV drug, dolutegravir.
GSK's new HIV drug formula could support longer dosing intervals
GSK said on Monday a new formulation of its HIV prevention and treatment drug could potentially be administered at least every four months, an improvement from the previous requirement of dosing every...
GSK CEO Emma Walmsley's total pay rises 51% to nearly 13 mln pounds in 2023
GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British drugmaker's annual report showed on Frida...
‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?
Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.
GSK settles another lawsuit on heartburn drug Zantac in California
GSK agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements made by the British drugm...
GSK's gonorrhoea drug meets primary goal in late-stage trial
British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.
First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says
British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus's progressi...
GSK's injectable HIV drug shows promise over daily pills
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing ch...
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.
GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel Oligonucleotides
SAN DIEGO--(BUSINESS WIRE)--GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel Oligonucleotides.
Hedge fund snaps up stake in Love Island maker ITV
A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price...